))
Cardiorenal Collaboration: Optimizing Multidisciplinary Care in the CvRM Patient
Manage episode 457680409 series 3381434
コンテンツは ReachMD によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、ReachMD またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
CME credits: 0.25
Valid until: 23-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/cardiorenal-collaboration-optimizing-multidisciplinary-care-in-the-cvrm-patient/26667/
The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.=
…
continue reading
Valid until: 23-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/cardiorenal-collaboration-optimizing-multidisciplinary-care-in-the-cvrm-patient/26667/
The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.=
453 つのエピソード
シェア
